The European Agency dé enne of m dé dicament has recommended dé to severely restrict the use of m dé drugs & agrave ; based bromocriptine, still commonly prescribed in Europe to stop the Mount dé e & milk after egrave, s birth, due to a small risk of ind effects dé serious sirables.
Particularly marketed dé e under the brand Parlodel as g é n é ; cal, bromocriptine is an active substance that acts on the nervous systems of dopamine.
It is used dé e in patients with Parkinson’s disease, but it is mainly prescribed to women who have just given birth and do not wish to breastfeed.
& quot; Bromocriptine should not & ecirc, be used dé e mani & egrave, re system dé matic for pr dé come or stop lactation & quot ;, indicates a recommendation approved dé e by the committee dé European dé in coordinating entity is dé European dé enne represented dé feeling the diff dé annuities national agencies m dé dicament.
The m dé drugs containing this substance should dé sormais & ecirc, be prescribed only when there & quot; Reasons imp dé fronted & quot; -Off & ecirc ; ter lactation, such as infection by the AIDS virus or & quot; For dé avoid any extra stress dé & commentary after egrave ; s loss of b é b é ; during or just after & egrave, s birth & quot;.
R dé dé valuation of bromocriptine had dé t & eacute; demand dé e last year by the agency fran & ccedil ; ease of m dé dicament who had dé tat side effects & quot; Rare but potentially serious cardiovascular & quot ;, mainly but also neurological and psychiatric.
The first reports date back ann dé es 90.
The first reports of effects ind dé sirables serious dé were occurring d & egrave, the ann s dé 90′s, especially in the United States, and had led & agrave ; strengthen information on pr dé job guarantees, especially among women pr dé feeling cardiovascular risk.
But the dosage and warnings dé were badly respect dé es, according ANSM reminder that the Mount é e is a milky & quot; physiological processes & quot;.
& quot; If the woman is not breastfeeding, lactation stops on its m & ecirc, me & a agrave ; two weeks & quot; she says on its website, while pr dé specifying that there are alternatives th dé peutic & agrave ; bromocriptine in the case o & ugrave ; lactation should ecirc & ; stopp be dé changed for reasons m dé dicales.
The CMDh for his part stressed that bromocriptine is available in the European Union countries European dé enne since 1973 and that the absolute number of severe side effects compared dé s the authority dé s is tr & egrave, s low, with a rate of incidence estimated dé agrave & 0.005 ; 0.4%.
Other indications of bromocriptine are not concerned dé es by the recommendation of the CMDh.
This last article egrave, re should dé sormais & ecirc, be ent dé rin dé e by the Commission European dé enne taking the dé final decision, which then will & ecirc, be followed by the Member States.